Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q4 2019 · 10-K
Revenue$8.31B$8.31B+7.1% vs Q4 2018 Net Income$1.05B$1.05B+60.4% vs Q4 2018 EPS Diluted$0.59$0.59+59.5% vs Q4 2018 Gross Profit$4,397,000,000+7.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$2,416,000,000+36.9% Free Cash Flowderived$1,982,000,000+52.7% Margins · derivedGross margin52.9%+0.3 pt vs Q4 2018
Operating margin16.7%+1.7 pt vs Q4 2018
Net margin12.6%+4.2 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 21, 2020 · 52 d after period end